Vericel Corporation
A biopharmaceutical company that grows patients' own cells into treatments for sports injuries and severe burns. Its flagship product, MACI, repairs torn knee cartilage, while Epicel grows a patient's skin cells into a permanent graft for large burns. Founded in 1989 as Aastrom Biosciences, it became Vericel in 2014 after buying Sanofi's cell-therapy business. The name plays on the word "cell," and thousands of burn patients have been treated with Epicel.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 13G/APassive | 2.8% | 1.46M | Aug 13, 2026 |
| Soleus Capital, LLC | 13G/APassive | 2.8% | 1.46M | Aug 13, 2026 |
| Soleus Capital Group, LLC | 13G/APassive | 2.8% | 1.46M | Aug 13, 2026 |
| Soleus Capital Management, L.P. | 13G/APassive | 2.8% | 1.46M | Aug 13, 2026 |
| Soleus GP, LLC | 13G/APassive | 2.8% | 1.46M | Aug 13, 2026 |
| Guy Levy | 13G/APassive | 2.8% | 1.46M | Aug 13, 2026 |
| Vanguard Capital Management | 13GPassive | 5.11% | 2.60M | Apr 30, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| Brown Capital Management, LLC | 13G/APassive | 3.87% | 1.95M | Nov 12, 2025 |
| STATE STREET CORPORATION | 13GPassive | 5.6% | 2.81M | Nov 10, 2025 |